Managing Patients Already Receiving Sunitinib in Second-Line GIST

This segment covers the panelists' discussion of what to do for patients already tolerating sunitinib in second-line KIT-mutant gastrointestinal stromal tumor (GIST) if bezuclastinib plus sunitinib is approved, a question they agree has no right answer. One panelist favors moving eligible patients onto the combination now through expanded access, pointing to a progression-free survival benefit larger than what the currently approved later-line agents have delivered combined, and suggesting the regimen may delay emergence of new resistance. The other takes a more patient-specific view, noting that while benefit was seen across mutation subsets, the confidence interval crossed unity in one primary mutation subgroup where sunitinib performs particularly well, so a patient with limited disease burden doing well might reasonably continue and switch at progression. Both note that overall survival data remain immature and that drug access will influence real-world decisions.